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Abstract 
Background: Hepatitis B virus (HBV) X protein (HBx) is a type of oncogenic protein involved in the progression of 
hepatocellular carcinoma (HCC) via interacting with host genes. Dysregulation of microRNAs (miRNAs) has been 
observed in HCC. This study aimed to investigate the role of HBx protein in the regulation of miR-19a, miR-122 and 
miR-223, and examine if these miRNAs involve in progression of malignant hepatocytes.
Methods: Quantitative real time PCR (qRT-PCR) was used to measure the expression of miR-19a, miR-122 and miR-
223 in patient samples and in HepG2 cells transfected with HBx or 1.3 fold HBV genome and also in HepG2.2.15 cells, 
which stably produces HBV. Their target mRNAs and proteins-PTEN, cyclin G1 and c-myc were measured by qRT-PCR 
and western blot, respectively. The effect of miR-19a, miR-122 and miR-223, and their respective target genes, on cell 
proliferation was analyzed using 5-ethynyl-2-deoxyuridine incorporation and MTT assay.
Results: MiR-19a showed an up-regulation in HBV-positive HCC patients compared to healthy controls and HBV-
negative HCC patients, while miR-122 and miR-223 showed a down-regulation compared to healthy controls, and 
miR-122 in HBV-positive HCC patients was also down-regulated when compared to HBV-negative HCC patients. MiR-
19a was found to be up-regulated in HepG2 cells transfected with HBx or 1.3 fold HBV genome, but down-regulated 
in HepG2.2.15 cells. MiR-122 and miR-223 were down-regulated in HBx or 1.3 fold HBV transfected HepG2 cells as well 
as in HepG2.2.15 cell. Their target mRNAs and corresponding proteins-PTEN was down-regulated, while cyclin G1 and 
c-myc were found to be up-regulated. Modulated expression of miR-19a, miR-122 and miR-223 enhanced cell prolif-
eration of HBx-transfected HepG2 cells, and rescue experiment further showed that their target genes-PTEN, cyclin 
G1and c-myc involved in cell proliferation of HBx-transfected HepG2 cells.
Conclusions: The expression of miR-19a, miR-122 and miR-223 were differentially regulated by HBx protein, the dif-
ferential expression of miR-19a, miR-122 and miR-223 plays an important role in cell proliferation of HCC. This study 
provides new insight into understanding how HBx protein interacts with miRNAs and subsequently regulates host 
function.
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Background
Hepatocellular carcinoma (HCC) is one of the most com-
mon forms of human cancer in the world and the leading 
cause of cancer-related death worldwide [1]. In China, 
chronic Hepatitis B Virus (HBV) infection is a major 
risk factor of HCC and liver cirrhosis [2]. Recent stud-
ies showed that HBV X protein (HBx) plays an important 
role in the pathogenic mechanism of HBV-associated 
HCC [3]. HBx is a multifunctional oncogenic protein, 
which interacts with various transcription factors (e.g., 
Oct-1, ATF-2, CREB) and modulates numerous signaling 
pathways (e.g., Src, AP-1, Ras, PI3 K/Akt, Jak/STAT and 
Wnt) [4, 5]. Recent studies also showed that HBx may 
increase telomerase activity to increase the lifespan of 
hepatocytes and subsequently transform them to malig-
nancies [6]. Therefore, HBx causes sustained changes 
in expression of cellular genes, which may result in 
enhanced hepatocytes growth and proliferation and lead 
to HCC.
MicroRNAs (miRNAs) are a class of endogenous, non-
coding, short RNAs, and negatively regulate the target 
genes via binding to the 3′ untranslated regions. MiRNAs 
have been shown to involve various biological processes, 
including cell proliferation, apoptosis, and differentiation 
[7]; and dysregulation of miRNAs have been associated 
with various types of cancers in human [8]. MiRNAs have 
been shown to function as oncogenes or tumor suppres-
sor genes during tumor development and progression [9]. 
Differential expression of miRNAs in HCC patients com-
pared to healthy subjects have been studied. MiR-224, 
miR-19a and miR-27a are upregulated in HCC; while 
miR-122, miR-223 and miR-101 are down-regulated 
in HCC [10]. Overexpression of miR-122 and miR-223 
directly results in the down-regulation of cyclin G1 and 
c-myc, respectively [11, 12].
Increasing efforts have been made in deciphering 
the interaction between HBx and miRNAs. One study 
showed that HBx negatively regulates let-7a, and down-
regulation of let-7a has been shown to increase cell pro-
liferation in HepG2 and SNU-182 cells [13]. MiR-27a is 
found to be up-regulated in HBV-positive HCC patients, 
and the up-regulation of miR-27a results in enhanced cell 
proliferation, migration, and invasion [14]. MiR-101 is 
negatively regulated by HBx and induces aberrant DNA 
methylation by targeting DNA methyl transferase 3A 
[15]. Although miRNAs have been shown to be regulated 
by HBV, how dysregulation of miRNAs influences liver 
cancer development and progression remains largely 
unknown.
In the present study, we first investigated differential 
expression of miR-19a, miR-122 and miR-223 in HBx or 
1.3 fold HBV transfected HepG2 cells and in HepG2.2.15 
cells, as well as in HBV-negative HCC patients and 
HBV-positive HCC patient samples. The role of HBx in 
modulation of expressions of these miRNAs in malignant 
hepatocytes was further validated by HBx gene knock 
down study. Next, we also examined whether differential 
expression of miR-19a, miR-122 and miR-223 is associ-
ated with the changes in expression levels of its target 
mRNAs and corresponding proteins (PTEN, cyclin G1 
and c-myc of miR-19a, miR-122 and miR-223, respec-
tively) [11, 12, 16]. Finally, we determined roles of miR-
19a, miR-122, miR-223 and their target genes, in cell 




Forty-three clinical HCC patients tested for HBV (gen-
otype C)-positive result and 30 clinical HCC patients 
tested for HBV-negative result were recruited in this 
study. For the healthy controls, 43 age and sex matched 
heathy individuals were recruited in this study, and these 
healthy control were subjected to blood test to rule out 
the HBV infection. The blood samples were taken from 
all these subjects for the quantitative real time PCR 
(qRT-PCR) analysis of miR-19a, miR-122 and miR-223 
expression. This study was approved by the Ethics Review 
Committees of the Fifth Affiliated Hospital of Guangzhou 
Medical University, and informed consent was obtained 
from all patients.
Cell culture
The cells of HepG2 (American Type Culture Collection, 
USA) and HepG2.2.15 (Shanghai Second Military Medi-
cal University), which constitutively replicated HBV, were 
cultured in Dulbecco’s modified Eagle medium (DMEM) 
with 10  % fetal bovine serum (Life Technologies Inc, 
Gaithersburg, MD, USA). Cell were incubated at 37 °C in 
a humidified atmosphere with 5 % CO2.
Plasmids and RNA oligonucleotides
The expression vector of pcDNA3.1-HBx was con-
structed by inserting HBx DNA fragments into 
pcDNA3.1 vector [17]. The 1.3 fold HBV genome (geno-
type C) fragment was amplified from pGEM-HBV1.3, 
and the amplified 1.3 fold HBV genome fragments was 
cloned into pcDNA3.1 plasmid for the construction of 
pcDNA3.1-HBV plasmid [18]. The expression vectors of 
pcDNA3.1-PTEN, pcDNA3.1-cylcin G1, and pcDNA3.1-
c-myc were purchased from Genepharma (Shanghai, 
China). HBx-siRNA, PTEN-siRNA, cyclin G1-siRNA 
and c-myc-siRNA was used to produce small interfer-
ing RNAs targeting HBx mRNA, PTEN mRNA, and 
cyclin G1 mRNA and c-myc mRNA respectively; miR-
19a inhibitor was used to reduce the expression level of 
Page 3 of 13Yu et al. J Transl Med  (2016) 14:122 
miR-19a, miR-122 and miR-223 mimics were used to 
increase the expression levels of miR-122 and miR-223, 
respectively; siRNA duplexes and miRNAs with non-spe-
cific sequences were designed as negative control (NC) 
(Ribobio, Guangzhou, China).
Cell transfection
HepG2 cells were seeded for 24 h, and transfected with 
Lipofecatmine 2000 and pcDNA3.1-HBx (2  µg) or 
pcDNA3.1-HBV (2 µg) or empty vector, pcDNA3.1 (2 µg) 
(Invitrogen, CA, USA) according to the manufacturer’s 
instruction. In the HBx and HBV plasmid transfection 
experiments, cells were used for RNA extraction 48  h 
post-transfection. In the HBx-siRNA experiment, HBx-
siRNA or its negative control was co-transfected with 
pcDNA3.1-HBx or pcDNA3.1-HBV plasmid in HepG2 
cells, and HBx-siRNA or its negative control was trans-
fected in HepG2.2.15 cells; RNA were extracted 24, 48, 
and 72  h post-transfection. For the miR-19a inhibitor, 
miR-122 and miR-223 mimics experiments, miR-19a 
inhibitor, miR-122 and miR-223 mimics or their nega-
tive controls were co-transfected with pcDNA3.1-HBx 
in HepG2 cells. For the PTEN overexpression, cyclin 
G1 and—cymc silence experiment, pcDNA3.1-PTEN, 
c-myc-siRNA or cyclin G1-siRNA, or their negative 
controls were co-transfected with pcDNA3.1-HBx in 
HepG2 cells; for the rescue experiment, miR-19a inhibi-
tor  +  PTEN-siRNA, miR-223 mimics  +  pcDNA3.1-
cyclin G1, or miR-122 mimics + pcDNA3.1-c-ymc were 
co-transfected with pcDNA3.1-HBx in HepG2 cells.
RNA extraction, reverse transcription PCR and qRT‑PCR 
analysis
Total RNA and miRNA fractions were isolated from 
blood samples, HepG2 cells and HepG2.2.15 cells using 
TRIzol reagent (Invitrogen, CA, USA). MiRNA extrac-
tion was performed using the miRNA Extraction Kit 
(Tiangen, Beijing, China). QRT-PCR was performed with 
SYBR Premix Ex Taq (TaKaRa). GAPDH was used as an 
internal control for mRNA, and RNU6B was used as the 
miRNA reference. The relative quantitative analysis of 
data were performed using 7000 system SDS software 
v1.2.3 (Applied Biosystems). The relative quantitation of 
target gene expression was obtained using the compara-
tive ΔΔCT method.
Western blot analysis
After 48 h of transfection, proteins were extracted from 
HepG2 cells and HepG2.2.15 cells, and their concentra-
tions were measured. Western blot analysis was per-
formed using anti-PTEN (1:500, Abcam Cambridge, MA, 
USA); anti-cyclin G1 (1: 500, Abcam Cambridge, MA, 
USA); anti-c-myc (1:500, Abcam Cambridge, MA, USA); 
anti-beta-catenin (1:2000, Abcam Cambridge, MA, 
USA), and beta-actin was used as loading control. Protein 
bands were quantified using Dentiometric scanner (Bio-
Rad-GS-800, USA).
Cell proliferation assay
After 24  h transfection, the 5-ethynyl-2-deoxyuridine 
(EdU) incorporation assay was performed using the Cell-
Light EdU imaging detecting kit according to the manu-
facturer’s instructions (Ribobio, Guangzhou, China) to 
assess cell proliferation. MTT assays were also used to 
assess cell proliferation from 24 h until 72 h post trans-
fection. The MTT assay was performed as follows: 20 μL 
of MTT (5 mg/mL) was added to each well and the plates 
were incubated at 37 °C for 4 h. The MTT medium mix-
ture was then removed and 150 μL of dimethyl sulfoxide 
was added to each well. The absorbance was measured at 
570 nm using a multi-well spectrophotometer.
Statistical analysis
All statistical analysis was carried out using GraphPad 
Prism version 6 (GraphPad Prism version 6.0, Inc. Cali-
fornia, USA). The differences among groups were ana-
lyzed by one-way ANOVA followed by Bonferroni’s 
multiple comparison tests or t test, as appropriate. All 
data are expressed as mean  ±  SEM. Differences were 
considered significant when P < 0.05.
Results
Expression of miRNAs among the HBV‑negative HCC 
patients, HBV‑positive HCC patients and healthy controls
In our study, all the HBV-positive HCC patients had 
a genotype C HBV positive results from the blood test. 
The expression levels of miR-19a, miR-122 and miR-223 
in blood serum from HBV-negative HCC patients, HBV-
positive HCC patients and age and sex matched healthy 
controls were analyzed by qRT-PCR. The expression level 
of miR-19a was higher in the blood serum from HBV-
negative HCC patients and HBV-positive HCC patients 
than that in healthy controls (Fig. 1a, n = 43, P < 0.05), 
and the expression level of miR-122 was lower in the 
blood serum from HBV-negative HCC patients and 
HBV-positive HCC patients compared to healthy con-
trols; while the up-regulation of miR-223 was only found 
in HBV-positive HCC patients but not in HBV-negative 
patients when compared to healthy controls (Fig.  1b, c, 
n = 30 or 43, P < 0.05). We further compared the expres-
sion levels of these miRs between HBV-negative HCC 
patients and HBV-positive HCC patients, and our results 
showed that HBV-positive HCC patients had a higher 
expression level of miR-19a and a lower expression 
level of miR-122 than HBV-negative patients (Fig. 1a, b, 
n = 30 and 43, P < 0.05); while there was no significant 
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differences in miR-223 expression level between HBV-
negative HCC patients and HBV-positive HCC patients 
(Fig. 1c, n = 30 or 43, P > 0.05).
Differential expression of miR‑19a, miR‑122, and miR‑223 
in HepG2 cells transfected with HBx or HBV and in 
HepG2.2.15 cells
QRT-PCR confirmed that expression levels of HBx was 
higher in HBx-transfected or 1.3 fold HBV transfected 
HepG2 cells compared to their respective controls (data 
not shown). QRT-PCR analysis showed that miR-19a was 
up-regulated, and miR-122 and miR-223 were down-reg-
ulated in HBx-transfected HepG2 cells compared to the 
HepG2 cells transfected with control vector, pcDNA3.1 
(Fig.  2a, n  =  3, P  <  0.05). Transfection of HepG2 cells 
with 1.3 fold HBV genome have showed similar results 
that miR-19a was up-regulated, and miR-122 and miR-
223 were down-regulated in 1.3 fold HBV-transfected 
HepG2 cells compared to the HepG2 cells transfected 
with control vector, pcDNA-3.1 (Fig. 2b, n = 3, P < 0.05). 
We also measured the expression of these miRNAs in a 
stable HBV producing cells, HepG2.2.15, and we found 
that all the miRNAs i.e. miR-19a, miR-122 and miR-223 
were down-regulated in the Hepg2.2.5 cells compared to 
its control, HepG2 cells (Fig. 2c, n = 3, P < 0.05).
Expression levels of PTEN, cyclin G1 and c‑myc in HepG2 
cells transfected with HBx or 1.3 fold HBV and in 
HepG2.2.15 cells
QRT-PCR analysis showed that PTEN mRNA was down-
regulated, and cyclin G1, c-myc mRNA were up-regu-
lated in HepG2 cells transfected with HBx compared to 
HepG2 cells transfected with pcDNA3.1 (Fig. 3a, n = 3, 
P < 0.05).Transfection of HepG2 cells with 1.3 fold HBV 
also caused down-regulation of PTEN mRNA, and up-
regulation of cyclin G1, c-myc mRNA compared to 
HepG2 cells transfected with pcDNA3.1 (Fig. 3b, n = 3, 
P  <  0.05). In the HepG2.2.15 cells; all the mRNAs-
PTEN, cyclin G1 and c-myc were up-regulated in the 
HepG2.2.15 cells when compared to its negative con-
trol, HepG2 cells (Fig. 3c, n = 3, P < 0.05). Western blot 
analysis further showed a decrease in PTEN protein level, 
and an increase in cyclin G1 and c-myc protein levels in 
HepG2 cells transfected with HBx or 1.3 fold HBV, and 
an increase in PTEN and cyclin G1 protein levels in 
HepG2.2.15 cells when compared to their respective con-
trols (Fig. 4, n = 3, P < 0.05).
Expression of miR‑19a, miR‑122, and miR‑223 was 
differentially regulated by HBx
The knock down effect of HBx mRNA on the expression 
of miR-19a, miR-122, and miR-223 examined in HepG2 
cells transfected with HBx plasmid; 1.3 fold HBV genome 
and in HepG2.2.15 cells. In HepG2 cells co-transfected 
with HBx plasmid and HBx-siRNA, the expression of 
miR-19a was lower 48 and 72  h post-transfection; the 
expression of miR-122 was higher 48 and 72 h post-trans-
fection, and the expression of miR-223 was higher 24, 48 
and 72 h post-transfection (Fig. 5a, n =  3, P < 0.05). In 
cells co-transfected with 1.3 fold HBV and HBx-siRNA, 
the expression of miR-19a was lower 72 h post-transfec-
tion; the expression of miR-122 and miR-223 was higher 
Fig. 1 Expression levels of miR-19a, miR-122, and miR-223 in healthy 
subjects and patients samples. qRT-PCR analysis of a miR-19a,  
b miR-122, and c miR-223 from blood serum samples in healthy con-
trol, HBV-negative HCC patients and HCC patients with HBV infection. 
HCC hepatocellular carcinoma, HBV hepatitis B virus. Data represents 
the mean ± SEM, n = 3, *P < 0.05; **P < 0.01 (One-way ANOVA fol-
lowed by Bonferroni test)
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Fig. 2 Expression levels of miR-19a, miR-122, and miR-223 in HepG2 cells transfected with HBx or HBV and in HepG2.2.15 cells. a qRT-PCR analysis 
of miR-19a, miR-122, and miR-223 in HepG2 cells transfected with HBx expressing plasmid pcDNA3.1-HBx or its control vector, pcDNA3.1; b qRT-PCR 
analysis of miR-19a, miR-122, and miR-223 in HepG2 cells transfected with 1.3 fold HBV expressing plasmid pcDNA3.1-HBV or its control vector, 
pcDNA3.1; c qRT-PCR analysis of miR-19a, miR-122, and miR-223 in HepG2.2.15 cells and its control, HepG2 cell lines. HBV hepatitis B virus, HBx HBV X 
protein. Data represents the mean ± SEM, n = 3, *P < 0.05; **P < 0.01; ***P < 0.001 (unpaired t-test)
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Fig. 3 mRNA expression levels of PTEN, cyclin G1 and c-myc in HepG2 cell lines transfected with HBx or HBV and in HepG2.2.15 cells. a mRNA 
expression levels of PTEN, cyclin G1 and c-myc in HepG2 cells transfected with HBx expression plasmid pcDNA3.1-HBx or its control vector, 
pcDNA3.1; b mRNA expression levels of PTEN, cyclin G1 and c-myc in HepG2 cells transfected with 1.3 fold HBV expression plasmid pcDNA3.1-HBV 
or its control vector, pcDNA3.1; c mRNA expression levels of PTEN, cyclin G1 and c-myc in HepG2.2.15 cells and its control, HepG2 cells. HBV hepati-
tis B virus, HBx HBV X protein. Data represents the mean ± SEM, n = 3, *P < 0.05; **P < 0.01; ***P < 0.001 (unpaired t-test)
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72  h post-transfection, and the expression of miR-122 
was also higher 48 and 72  h post-transfection (Fig.  5b, 
n = 3, P < 0.05). However, the expression levels of miR-
19a was higher in HepG2.2.15 cells transfected with HBx-
siRNA 24  h post-transfection; and the expression levels 
of miR-122 and miR-223 were also higher in HepG2.2.15 
cells transfected with HBx-siRNA 24  h and 48  h post-
transfection (Fig. 5c, n = 3, P < 0.05).
The proliferation of HepG2 cells was enhanced by HBx
We also examined the effect of HBx on hepatoma cell 
proliferation. EdU incorporation assay and MTT assay 
results showed that HBx plasmid transfected HepG2 cells 
had a higher proliferation ability compared to HepG2 
cells transfected with pcDNA3.1; and RNA interference 
targeting HBx mRNA abolished HBx-induced prolifera-
tion of HepG2 cells (Fig. 6, n = 3, P < 0.05).
MiR‑19a, miR‑122 and miR‑223 contribute 
to HBx‑mediated proliferation of HepG2 cells
The function of miR-19a, miR-122 and miR-223 in HBx-
transfected HepG2 cells was also investigated. Previous 
results showed that miR-19a was up-regulated, miR-122 
and miR-223 were down-regulated in HBx-transfected 
HepG2 cells. We elucidate the function of miR-19a by 
silencing the expression of miR-19a; and the function of 
miR-122 and miR-223 was determined by overexpression 
of miR-122 and miR-223. EdU incorporation assay and 
MTT assay results showed that silencing of miR-19a 
inhibited the growth of HBx-transfected HepG2 cells 
(Fig. 7a, n = 3, P < 0.05); the growth of HBx-transfected 
HepG2 cells was also inhibited by overexpression of miR-
122 and miR-223, respectively (Fig. 7b, c, n = 3, P < 0.05).
PTEN, cyclin G1, and c‑myc contribute to HBx‑mediated 
proliferation of HepG2 cells
The function of PTEN, c-myc, and cyclin G1 in HBx- 
transfected HepG2 cells was further examined. EdU 
incorporation assay showed that transfection of PTEN 
expressing vector (pcDNA3.1-PTEN), cyclin G1 siRNA 
(si–cyclin G1) or c-myc siRNA (si–c-myc) inhibited the 
proliferation of HBx-transfected HepG2 cells (Fig.  8, 
n  =  3, P  <  0.05). Further rescue experiment showed 
that co-transfection with pcDNA3.1-PTEN and miR-
19a inhibitor, pcDNA3.1-c-myc and miR-122 mimics or 
pcDNA3.1-cyclin G1 and miR-223 mimics restored the 
inhibitory effects (Fig. 8, n = 3, P < 0.05).
Discussion
It is well known that HBx plays a key role in viral patho-
genesis and hepatocarcinogenesis via modulation of cel-
lular genes, which subsequently changes the cell signaling 
pathway and other cellular processes [3, 19, 20]. Enor-
mous studies have shown that miRNAs involve in cell 
Fig. 4 Protein expression levels of PTEN, cyclin G1 and c-myc in HepG2 cell lines transfected with HBx or 1.3 fold HBV and in HepG2.2.15 cells.  
a Western blot analysis of PTEN, cyclin G1 and c-myc in HepG2 cells transfected with HBx expression plasmid pcDNA3.1-HBx or its control vector, 
pcDNA3.1; b Western blot analysis of PTEN, cyclin G1 and c-myc in HepG2 cells transfected with 1.3 fold HBV expression plasmid pcDNA3.1-HBV or 
its control vector, pcDNA3.1; c Western blot analysis of PTEN, cycling G1 and c-myc in HepG2.2.15 cells and its control, HepG2 cells. HBV hepatitis B 
virus, HBx HBV X protein. Data represents the mean ± SEM, n = 3, *P < 0.05 (unpaired t-test)
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proliferation, tumorigenesis, apoptosis, invasion/metas-
tasis and angiogenesis of cancer cells [8, 21]. In HBV-
related HCC, miRNAs have been found to be involved in 
viral replication, latency, epigenetic modulation, interact-
ing with viral products or indirectly alters cancer-related 
pathways via interacting with HBx [22]. In the present 
study, we first demonstrated that miR-19a, miR-122 and 
miR-223 were differentially modulated by HBx in HepG2 
cells and HepG2.2.15 cells, and similar findings were fur-
ther confirmed in the blood serum samples from HBV-
positive HCC patients. Further studies also showed that 
modulated expression of miR-19a, miR-122 and miR-223 
promoted cell proliferation of HBx-transfected HepG2 
cells.
PTEN, cyclin G1 and c-myc, involving in cell prolif-
eration, was found as targets for miR-19a, miR-122, and 
Fig. 5 Expression levels of miR-19a, miR-122, and miR-223 after silence of HBx in HepG2 cell lines transfected with HBx or HBV and in HepG2.2.15 
cells. a qRT-PCR analysis of miR-19a, miR-122, and miR-223 in HepG2 cells co-transfected with pcDNA3.1-HBx and HBx-siRNA or its negative control 
(NC); b qRT-PCR analysis of miR-19a, miR-122, and miR-223 in HepG2 cells co-transfected with pcDNA3.1-HBV and HBx-siRNA or its negative control 
(NC); c qRT-PCR analysis of miR-19a, miR-122, and miR-223 in HepG2.2.15 cells and its negative control, HepG2 cells. HBV hepatitis B virus, HBx HBV X 
protein. Data represents the mean ± SEM, n = 3, *P < 0.05; **P < 0.01 (unpaired t-test)
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miR-223 respectively [11, 12, 16]. PTEN is known to be 
tumor suppressor that is mutated in a large number of 
cancers at high frequency [23]. It negatively regulates 
intracellular levels of phosphatidylinostitol-3,4,5-tris-
phosphate in cells and functions as a tumor suppressor 
by negatively regulating AKT/PKB signaling pathway 
[24]. MiR-19a has been shown to be an onco-miRNA 
by targeting PTEN in several studies [16, 25, 26]. In the 
present study, we found miR-19a was up-regulated in 
HBx–transfected HepG2 cells; and similar results were 
also found in HepG2 cells transfected with 1.3 fold HBV. 
The up-regulation of miR-19a in HBV-positive HCC 
patients in present study was in consistent with studies 
showing that miR-19a was both up-regulated in HCC 
tissues and blood serum from HCC patients [27, 28]. 
However, in HepG2.2.15 cells, we found the expression of 
miR-19a is lower compared to HepG2 cells, and its tar-
get PTEN mRNA and protein were up-regulated. We are 
still unclear of the underlying mechanism of this interest-
ing finding. However, studies have shown that chronic 
HBV-induced HCC involves covalently closed circular 
episomal HBV genome as well as HBV DNA integrated 
host chromosome; trans-activation of HBx from cova-
lently close circular episomal HBV genome may involve 
in cytoplasmic regulation of cell signaling pathway, which 
leads to hepatocarcinogenesis; while the HBV integra-
tion into host chromosome may play a role in modula-
tion of genes that are responsible for cell proliferation 
[19, 29]. Therefore, we proposed that HBV employs both 
mechanism in HCC to differentially modulate miR-19a 
expression between HepG2.2.15 cells and HepG2 cells. 
Further studies may be required to clarify the underlying 
mechanism.
Cyclin G1, a target of miR-122, has been found to nega-
tively regulate p53 protein stability by acting on PP2A, 
and its oncogenic role has been well documented in 
different human cancers [11, 30]. In the present study, 
miR-122 was found to be down-regulated in HBx-trans-
fected HepG2 cells. Similar results were also observed in 
HepG2 cells transfected with 1.3 fold HBV genome and 
in HepG2.2.15 cells. In addition, miR-122 was also down-
regulated in HBV-positive HCC patients [31]. Knock 
down of miR-122 experiment further confirmed that 
expression of miR-122 was dependent on HBx; and the 
regulation of HBx on miR-122 is possible via down-regu-
lation of Gld2 [32].
C-myc is a regulator gene that codes for a transcrip-
tion factor and plays a key role in cell cycle progression, 
apoptosis and cellular transformation [33], and over-
expression of c-myc has been found in various types of 
cancers, including HCC [34, 35]. Present studies demon-
strated that miR-223 is down-regulated in HBx or HBV 
transfected HepG2 cells and in HepG2.2.15 cells; and 
similar result was also found in clinically HBV-positive 
HCC patients, and our results from clinical samples were 
consistent with previous studies, which examined the 
expression of miRNAs in HBV-positive HCC patients. 
MiR-223 has also been shown to be tumor-suppressive 
in HCC [31], and repression of miR-223 has been asso-
ciated with up-regulation of c-myc in HCC [12]. Wong 
et al., demonstrated that miRNA is commonly repressed 
in HCC and potentiates expression of Stathmin 1 [36], 
and further study also showed that miR-223 was epige-
netically regulated by sulfatide and inhibits migration 
of HCC cells [37]. However, in certain types of cancers, 
miR-233 was found to be oncogenic. Notably, miR-233 
is highly expressed in gastric cancer and promotes cell 
proliferation and invasion by targeting EPB41L3 [38]; 
Fig. 6 Effect of HBx on the cell proliferation in HepG2 cells. a The cell 
proliferation ability of hepatoma cells was analyzed using the EdU 
incorporation assay; b the cell proliferation ability of hetatoma cells 
was analyzed using MTT assay. HBx HBV X protein. Data represents 
the mean ± SEM, n = 3, *P < 0.05 (One-way ANOVA followed by 
Bonferroni test)
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and overexpression of miR-223 was found to correlate 
with tumor metastasis and poor prognosis in patients 
with colorectal cancer and plays an oncogenic role [39, 
40]. Therefore, the role of miR-223 may be opposing in 
different types of cancer or tumor cell lines via different 
functional genes. In our study, the results showed the 
overexpression of c-myc mRNA and protein is associ-
ated with a down-regulation of miR-223 in HBx or 1.3 
fold HBV-transfected HepG2 cells and in HepG2.2.15 
cells, and up-regulation suppressed the cell growth in the 
HBx-transfected HCC, which may suggest that miR-233 
is tumor-suppressive in HBV-related HCC.
Cell proliferation assay showed that HBx promoted 
cell proliferation of HepG2 cells, and this finding is 
consistent with previous studies [41]. We further con-
firmed that roles of miR-19a, miR-122 and miR-233 in 
cell proliferation in HBx-transfected HepG2 cells, with 
miR-19a being oncogenic, and miR-122 and miR-223 
Fig. 7 The role of miR-19a, miR-122, and miR-223 in HBx-mediated growth of HepG2 cells. a The proliferation ability of HepG2-pcDNA3.1-HBx cells 
was analyzed using the EdU incorporation and MTT assays after miR-19a inhibitor treatment; b the proliferation ability of HepG-pcDNA3.1 cells was 
analyzed using the EdU incorporation and MTT assays after miR-122 mimics treatment; c the proliferation ability of HepG-pcDNA3.1 cells was ana-
lyzed using the EdU incorporation and MTT assays after miR-223 mimics treatment. Data represents the mean ± SEM, n = 3, *P < 0.05; **P < 0.01; 
***P < 0.001 (unpaired t-test)
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being tumor suppressive. MiR-19a has been found to 
promote cell proliferation in various types of cancers 
such as bladder cancer, gastric cancer, prostate can-
cer via targeting different transcriptional factors [16, 
42, 43]; and in HCC patients, miR-19a was found to be 
up-regulated in the blood serum, and played inhibitory 
roles in HCC via regulating cyclin D1 expression [28], 
Melegari et  al., further demonstrated miR-19a was up-
regulated in HBV-positive HCC and this up-regulation 
is attributed to HBx [44]. In the present study, we fur-
ther explored the role of miR-19a in HBV-related HCC 
and in three different HCC cell lines, and our results 
suggest that miR-19a is oncogenic in HBV-related HCC, 
and its oncogenic role may be via regulating PTEN reg-
ulation, although the underlying mechanism of miR-19a 
involved in hepatocytes cell proliferation needs further 
investigation. MiR-122 has been found to be tumor sup-
pressive in liver cancer, dysregulation of miR-122a has 
been found in HBV-related HCC and liver cirrhosis [31, 
45]. The role of miR-122 in cell proliferation may involve 
up-regulation of PTTG-1 binding protein [46] and cyc-
lin G1 [11] in HBx-transfected HepG2 cells. Down-
regulation of miR-223 has been verified in several HCC 
studies [47, 48] and its down-regulation is associated 
with the epigenetic regulation by highly expressed sul-
fatide and involved in tumor metastasis; and the regu-
latory role of miR-223 in hepatocarcinogenesis may 
involve modulation of several targets including integrin 
αV and c-myc [12, 37]. Our rescue experiments further 
confirmed that these miRs regulated cell proliferation 
via targeting their respective targets, i.e. PTEN, cyclin 
G1 and c-myc. Collectively, our results demonstrated 
that dysregulation of miR-19a, miR-122 and miR-223 in 
sera may be associated with the pathogenesis of HBV-
related HCC, which may suggest that serum miR-19a, 
miR-122 and miR223 might serve as a novel and poten-
tial noninvasive biomarker for prognosis of HBV-related 
HCC; and modulation of these miRs expression may 
provide novel therapeutics for the treatment of HCC. 
However, the underlying mechanisms of miR-19a, miR-
122 and miR-223, and their respective targets involv-
ing in cell proliferation in HBx-transfected HepG2 still 
need further investigation.
Conclusions
In conclusion, present studies demonstrate that HBx pro-
tein differentially regulated the expression of miR-19a, 
miR-122 and miR-223, and its regulation may be associ-
ated with genotype C; miR-19a, miR-122 and miR-223 
might also involve in the hepatocarcinogenesis in HBV-
related HCC. Our results may provide new insight into 
understanding the interaction between HBx and miRNAs 
and their regulatory roles in HBV-related HCC.
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